AU · rank #15 · 2026-09-09
CORT
NASDAQ · $11.94B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.079 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$1.20 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.153 |
| Analyst upside Consensus target $141.00 | +23.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +22.19% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $126.38 |
| Market cap (USD) | $11.94B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Corcept Therapeutics is a profitable specialty biotech generating over $200M per quarter from Korlym and its authorized generic for Cushing's syndrome, with newly launched Lifyorli as a second commercial product.
Rationale
The analyst_upside_pct of 23.7% is reinforced by a massive 535% earnings surprise, 32% YoY revenue growth, raised full-year guidance to $1.1–$1.2B, and 100% revision agreement among analysts lifting EPS estimates over 30/60/90-day windows, suggesting the consensus target has not yet fully caught up to the new earnings power.
Material risks
- 1Revenue concentration risk is acute — Korlym plus its authorized generic account for ~$208M of $256M in quarterly revenue, meaning any generic competitor entry, formulary exclusion, or reimbursement pressure would directly collapse the earnings base underpinning the analyst upside thesis.
- 2With only 4 analysts covering the name, a target dispersion of 81.6%, net analyst upgrades negative over 90 days, and zero insider buying in 90 days, the 23% upside signal rests on thin, potentially stale sell-side conviction rather than broad institutional consensus building.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.